SK7112002A3 - Use of pyrimido-pyrimidine - Google Patents

Use of pyrimido-pyrimidine Download PDF

Info

Publication number: SK7112002A3
Authority: SK; Slovakia
Prior art keywords: dipyridamole; pyrimido; pyrimidine; disease; manufacture
Prior art date: 1999-10-22

Application number

SK711-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Wolfgang Eisert

Original Assignee

Boehringer Ingelheim Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-22

Filing date

2000-10-14

Publication date

2002-09-10

2000-10-14 Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma

2002-09-10 Publication of SK7112002A3 publication Critical patent/SK7112002A3/sk

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK711-2002A 1999-10-22 2000-10-14 Use of pyrimido-pyrimidine SK7112002A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP99121121A EP1093814A1 (fr)	1999-10-22	1999-10-22	Utilisation du dipyridamole ou du mopidamol dans la fabrication d'un médicament pour le traitement et la prévention des troubles de la microcirculation dépendants de la fibrine
PCT/EP2000/010123 WO2001030353A1 (fr)	1999-10-22	2000-10-14	Utilisation de dipyridamole ou de mopidamol dans la fabrication d'un medicament de traitement et de prevention de troubles de la microcirculation lies a la fibrine

Publications (1)

Publication Number	Publication Date
SK7112002A3 true SK7112002A3 (en)	2002-09-10

Family

ID=8239263

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK711-2002A SK7112002A3 (en)	1999-10-22	2000-10-14	Use of pyrimido-pyrimidine

Country Status (27)

Country	Link
US (2)	US20030149058A1 (fr)
EP (2)	EP1093814A1 (fr)
JP (1)	JP2003512431A (fr)
KR (1)	KR20020040901A (fr)
CN (2)	CN1823780A (fr)
AR (1)	AR026197A1 (fr)
AU (1)	AU784124B2 (fr)
BG (1)	BG106609A (fr)
BR (1)	BR0014946A (fr)
CA (1)	CA2387486C (fr)
CZ (1)	CZ20021487A3 (fr)
EA (1)	EA200200448A1 (fr)
EE (1)	EE200200214A (fr)
HK (1)	HK1048597A1 (fr)
HR (1)	HRP20020342A2 (fr)
HU (1)	HUP0203249A3 (fr)
IL (1)	IL148974A0 (fr)
MX (1)	MXPA02003901A (fr)
NO (1)	NO20021784D0 (fr)
NZ (1)	NZ518525A (fr)
PE (1)	PE20010747A1 (fr)
PL (1)	PL354591A1 (fr)
SK (1)	SK7112002A3 (fr)
TR (1)	TR200201089T2 (fr)
WO (1)	WO2001030353A1 (fr)
YU (1)	YU30002A (fr)
ZA (1)	ZA200203156B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1093814A1 (fr) *	1999-10-22	2001-04-25	Boehringer Ingelheim Pharma KG	Utilisation du dipyridamole ou du mopidamol dans la fabrication d'un médicament pour le traitement et la prévention des troubles de la microcirculation dépendants de la fibrine
US7064130B2 (en) *	2001-04-20	2006-06-20	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
DE10119680A1 (de) *	2001-04-20	2002-11-14	Boehringer Ingelheim Pharma	Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation
KR100917082B1 (ko)	2001-10-05	2009-09-15	콤비네이토릭스, 인코포레이티드	면역염증 질환의 치료를 위한 조합
MY131170A (en) *	2002-03-28	2007-07-31	Nissan Chemical Ind Ltd	Therapeutic agent for glomerular disease
DE10335027A1 (de) *	2003-07-31	2005-02-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Angiotensin II Rezeptor Antagonisten
WO2004069254A2 (fr) *	2003-02-07	2004-08-19	Boehringer Ingelheim International Gmbh	Utilisation du dipyridamole ou mopidamole pour le traitement et la prevention de troubles dependant de mmp-9
DE10306179A1 (de) *	2003-02-13	2004-08-26	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
EP2062580A1 (fr) *	2003-04-24	2009-05-27	Boehringer Ingelheim International GmbH	Utilisation de dipyridamole ou mopidamole pour le traitement et la prévention de maladies et de troubles thromboemboliques provoqués par la formation en excès de thrombine et/ou par l'expression élevée de récepteurs de la thrombine
JP2005060359A (ja) *	2003-08-13	2005-03-10	Boehringer Ingelheim Pharma Gmbh & Co Kg	血管系病態の治療及び予防のためのジピリダモール、アセチルサリチル酸及びアンギオテンシンｉｉ拮抗薬の使用
TW200517114A (en) *	2003-10-15	2005-06-01	Combinatorx Inc	Methods and reagents for the treatment of immunoinflammatory disorders
CN101068570A (zh)	2004-05-13	2007-11-07	贝林格尔·英格海姆国际有限公司	双嘧达莫治疗血小板抑制剂的抗药性的用途
AU2005249794A1 (en)	2004-06-04	2005-12-15	Teva Pharmaceutical Industries, Ltd.	Pharmaceutical composition containing irbesartan
JP2008534681A (ja) *	2006-02-09	2008-08-28	テバファーマシューティカルインダストリーズリミティド	ジピリダモール持続放出製剤及びそれを調製のための方法
US20100062066A1 (en) *	2006-11-14	2010-03-11	Acusphere, Inc	Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration
WO2014178891A1 (fr)	2013-04-30	2014-11-06	Otitopic Inc.	Formulations de poudre sèche et procédés d'utilisation
TW201503900A (zh) *	2013-07-29	2015-02-01	ren-zheng Lin	增強治療急性中風之抗血小板藥物之遞送方法及其組合物
CN107106541A (zh) *	2015-01-28	2017-08-29	瑞采生技有限公司	用于增强PPARγ表现及核转位之化合物及其医疗用途
KR101736832B1 (ko)	2017-02-28	2017-05-17	초당약품공업 주식회사	디피리다몰을 유효 성분으로 함유하는 신장 질환 치료용 의약 조성물
CN111346228B (zh) *	2018-12-21	2022-01-14	广州市妇女儿童医疗中心	胃肠道疾病的免疫机制及治疗药物
CN114432451B (zh) *	2018-12-21	2024-02-09	广州市妇女儿童医疗中心	胃肠道疾病的免疫机制及治疗药物
CN118477044A (zh) *	2023-02-13	2024-08-13	智泽童康(广州)生物科技有限公司	一种双嘧达莫的矫味组合物、干混悬剂及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3031450A (en) *	1959-04-30	1962-04-24	Thomae Gmbh Dr K	Substituted pyrimido-[5, 4-d]-pyrimidines
DE2735830A1 (de) *	1977-08-09	1979-03-01	Thomae Gmbh Dr K	Antithrombotische arzneimittelkombination und verfahren zu ihrer herstellung
DE3000979A1 (de) *	1980-01-12	1981-07-23	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) *	1981-06-19	1983-01-05	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue orale dipyridamolformen
DE3237575A1 (de) *	1982-10-09	1984-04-12	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue orale mopidamolformen
JPS6153271A (ja) *	1984-08-24	1986-03-17	Kaken Pharmaceut Co Ltd	ローダニン誘導体
ATE50497T1 (de) *	1984-07-21	1990-03-15	Hoechst Ag	Kombinationspraeparat aus pyrimido-pyrimidinen und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung.
DE3627423A1 (de) *	1986-08-13	1988-02-18	Thomae Gmbh Dr K	Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
US5242921A (en) *	1988-04-27	1993-09-07	Yale University	Compositions and methods for treating cutaneous hyperproliferative disorders
SU1685450A1 (ru) *	1989-03-10	1991-10-23	Московский медицинский стоматологический институт им.Н.А.Семашко	Способ лечени скаленус-синдрома при шейном остеохондрозе
IT1239064B (it) *	1990-05-14	1993-09-20	Fidia Spa	Uso terapeutico del dipiridamolo
US5639482A (en) *	1993-11-10	1997-06-17	Crary; Ely J.	Composition for control and prevention of diabetic retinopathy
CN1111985A (zh) *	1994-05-06	1995-11-22	王志刚	阿司匹林与潘生丁复方多层片的制备方法
US5498613A (en) *	1994-06-07	1996-03-12	The University Of Southern California	Dipyridamole and analogs thereof in preventing adhesion formation
US5968983A (en) *	1994-10-05	1999-10-19	Nitrosystems, Inc	Method and formulation for treating vascular disease
US5620409A (en) *	1995-09-15	1997-04-15	The Research Foundation Of State University Of New York	Method for inhibiting clot formation
CN1152436A (zh) *	1995-12-22	1997-06-25	王介明	一种治疗缺血性脑血管病和脑血栓的康复液及其制法
PL337223A1 (en) *	1997-06-05	2000-08-14	Lilly Co Eli	Method of treating thrombotic disorders
CN1108798C (zh) *	1999-01-26	2003-05-21	广东药学院	一种治疗、预防血栓形成及中风的复方制剂及其制备方法
CA2378257A1 (fr) *	1999-08-10	2001-02-15	William E. Sponsel	Procede permettant d'augmenter l'ecoulement sanguin dans le nerf optique, la retine et la choroide afin de faciliter la preservation de la vue
EP1093814A1 (fr) *	1999-10-22	2001-04-25	Boehringer Ingelheim Pharma KG	Utilisation du dipyridamole ou du mopidamol dans la fabrication d'un médicament pour le traitement et la prévention des troubles de la microcirculation dépendants de la fibrine
DE10011482B4 (de) *	2000-03-09	2004-06-09	Fresenius Hemocare Gmbh	Verfahren zum Herstellen eines Adsorbens zum Absenken der Konzentration von Fibrinogen und/oder Fibrin, Adsorbens und Verwendung des Adsorbens zur Herstellung eines Adsorbers
US6979462B1 (en) *	2000-10-03	2005-12-27	Mutual Pharmaceutical Co., Inc.	Stabilization of solid drug formulations
US7064130B2 (en) *	2001-04-20	2006-06-20	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
US20020187187A1 (en) *	2001-04-21	2002-12-12	Toshimitsu Ohki	Fast disintegrating meloxicam tablet
US7064103B2 (en) *	2002-01-04	2006-06-20	Becton, Dickinson And Company	Binding protein as biosensors
US20030180282A1 (en) *	2002-03-25	2003-09-25	Victor Serebruany	Method of treatment of thrombotic events
WO2004069254A2 (fr) *	2003-02-07	2004-08-19	Boehringer Ingelheim International Gmbh	Utilisation du dipyridamole ou mopidamole pour le traitement et la prevention de troubles dependant de mmp-9
EP2062580A1 (fr) *	2003-04-24	2009-05-27	Boehringer Ingelheim International GmbH	Utilisation de dipyridamole ou mopidamole pour le traitement et la prévention de maladies et de troubles thromboemboliques provoqués par la formation en excès de thrombine et/ou par l'expression élevée de récepteurs de la thrombine

1999
- 1999-10-22 EP EP99121121A patent/EP1093814A1/fr not_active Withdrawn
2000
- 2000-10-14 YU YU30002A patent/YU30002A/sh unknown
- 2000-10-14 CN CNA2005101362547A patent/CN1823780A/zh active Pending
- 2000-10-14 JP JP2001532773A patent/JP2003512431A/ja active Pending
- 2000-10-14 IL IL14897400A patent/IL148974A0/xx unknown
- 2000-10-14 HU HU0203249A patent/HUP0203249A3/hu unknown
- 2000-10-14 SK SK711-2002A patent/SK7112002A3/sk not_active Application Discontinuation
- 2000-10-14 MX MXPA02003901A patent/MXPA02003901A/es unknown
- 2000-10-14 NZ NZ518525A patent/NZ518525A/en unknown
- 2000-10-14 AU AU12721/01A patent/AU784124B2/en not_active Ceased
- 2000-10-14 EA EA200200448A patent/EA200200448A1/ru unknown
- 2000-10-14 CA CA002387486A patent/CA2387486C/fr not_active Expired - Fee Related
- 2000-10-14 WO PCT/EP2000/010123 patent/WO2001030353A1/fr not_active Ceased
- 2000-10-14 BR BR0014946-2A patent/BR0014946A/pt not_active IP Right Cessation
- 2000-10-14 TR TR2002/01089T patent/TR200201089T2/xx unknown
- 2000-10-14 PL PL00354591A patent/PL354591A1/xx not_active Application Discontinuation
- 2000-10-14 HK HK03100835.6A patent/HK1048597A1/zh unknown
- 2000-10-14 EP EP00974393A patent/EP1225900A1/fr not_active Withdrawn
- 2000-10-14 CZ CZ20021487A patent/CZ20021487A3/cs unknown
- 2000-10-14 HR HR20020342A patent/HRP20020342A2/hr not_active Application Discontinuation
- 2000-10-14 EE EEP200200214A patent/EE200200214A/xx unknown
- 2000-10-14 CN CNB008146756A patent/CN100411620C/zh not_active Expired - Fee Related
- 2000-10-14 KR KR1020027005042A patent/KR20020040901A/ko not_active Ceased
- 2000-10-20 AR ARP000105541A patent/AR026197A1/es unknown
- 2000-10-20 PE PE2000001127A patent/PE20010747A1/es not_active Application Discontinuation
2002
- 2002-04-12 BG BG106609A patent/BG106609A/bg unknown
- 2002-04-16 NO NO20021784A patent/NO20021784D0/no not_active Application Discontinuation
- 2002-04-22 ZA ZA200203156A patent/ZA200203156B/xx unknown
2003
- 2003-02-27 US US10/376,072 patent/US20030149058A1/en not_active Abandoned
2007
- 2007-12-18 US US11/958,504 patent/US20080113934A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20080113934A1 (en)	2008-05-15
HUP0203249A2 (hu)	2003-01-28
CN100411620C (zh)	2008-08-20
AU784124B2 (en)	2006-02-09
HK1048597A1 (zh)	2003-04-11
CZ20021487A3 (cs)	2002-10-16
HUP0203249A3 (en)	2004-12-28
MXPA02003901A (es)	2002-12-13
CA2387486A1 (fr)	2001-05-03
NO20021784L (no)	2002-04-16
YU30002A (sh)	2004-12-31
JP2003512431A (ja)	2003-04-02
WO2001030353A1 (fr)	2001-05-03
EP1225900A1 (fr)	2002-07-31
PL354591A1 (en)	2004-01-26
TR200201089T2 (tr)	2002-09-23
AR026197A1 (es)	2003-01-29
ZA200203156B (en)	2003-08-27
BG106609A (bg)	2003-02-28
CA2387486C (fr)	2009-07-21
IL148974A0 (en)	2002-11-10
CN1823780A (zh)	2006-08-30
HRP20020342A2 (en)	2003-10-31
KR20020040901A (ko)	2002-05-30
AU1272101A (en)	2001-05-08
US20030149058A1 (en)	2003-08-07
PE20010747A1 (es)	2001-07-24
EP1093814A1 (fr)	2001-04-25
BR0014946A (pt)	2002-06-18
CN1382052A (zh)	2002-11-27
NZ518525A (en)	2004-04-30
NO20021784D0 (no)	2002-04-16
EA200200448A1 (ru)	2002-10-31
EE200200214A (et)	2003-06-16

Publication	Publication Date	Title
SK7112002A3 (en)	2002-09-10	Use of pyrimido-pyrimidine
US20090192123A1 (en)	2009-07-30	Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of Thrombin and/or by elevated expression of Thrombin receptors
US20050282830A1 (en)	2005-12-22	Use of dipyridamole or mopidamole for treatment and prevention of MMP-9-dependent disorders
US20080076786A1 (en)	2008-03-27	Use of radical-scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
AU2002338396B2 (en)	2007-10-18	Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
AU2002338396A1 (en)	2003-04-17	Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
WO2009080301A1 (fr)	2009-07-02	Traitement et prévention des lésions cérébrales ischémiques et des troubles cognitifs cérébrovasculaires, au moyen d'un régime de traitement composé de dipyridamole et d'un bloqueur du récepteur de l'angiotensine ii, chez des patients ayant subi un accident cérébrovasculaire

Legal Events

Date	Code	Title	Description
2010-06-07	FC9A	Refused patent application